Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results

被引：0
|
作者：
Gettinger, S. N. [1 ]
Bazhenova, L. A. [2 ]
Salgia, R. [3 ]
Langer, C. J. [4 ]
Gold, K. [5 ]
Rosell, R. [6 ]
Shaw, A. T. [7 ]
Weiss, G. J. [8 ]
Dorer, D. J. [9 ]
Rivera, V. M. [10 ]
Kerstein, D. [11 ]
Camidge, D. R. [12 ]
机构：
[1] Yale Canc Ctr, Med Oncol, New Haven, CT USA
[2] Univ Calif San Diego, Moores Canc Ctr, Med Oncol, La Jolla, CA 92093 USA
[3] Univ Chicago Med, Biomed Sci, Chicago, IL USA
[4] Univ Penn, Abramson Canc Ctr, Thorac Oncol, Philadelphia, PA 19104 USA
[5] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[6] Catalan Inst Oncol, Med Oncol, Barcelona, Spain
[7] Massachusetts Gen Hosp, Dept Med, Ctr Canc, Boston, MA 02114 USA
[8] Canc Treatment Ctr Amer, Western Reg Med Ctr, Goodyear, AZ USA
[9] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA 02139 USA
[10] ARIAD Pharmaceut Inc, Preclin & Translat Res, Cambridge, MA 02139 USA
[11] ARIAD Pharmaceut Inc, Clin Res, Cambridge, MA 02139 USA
[12] Univ Colorado, Ctr Canc, Med Oncol, Aurora, CO USA
来源：
LUNG CANCER | 2016年 / 91卷
关键词：
D O I：
10.1016/S0169-5002(16)30073-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
56
引用
收藏
页码：S20 / S21
页数：2
相关论文
共 50 条
  • [41] Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma (vol 13, pg 775, 2015)
    Ceccon, M.
    Mologni, L.
    Giudici, G.
    Piazza, R.
    Pirola, A.
    Fontana, D.
    MOLECULAR CANCER RESEARCH, 2015, 13 (10) : 1441 - 1441
  • [42] Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials
    Huber, R.
    Gettinger, S.
    Kim, D. -W
    Bazhenova, L.
    Hansen, K.
    Tiseo, M.
    Langer, C.
    Paz-Ares Rodriguez, L.
    West, H.
    Reckamp, K.
    Weiss, G.
    Smit, E.
    Hochmair, M.
    Kim, S. -W
    Ahn, M. -J
    Kim, E.
    Groen, H.
    Pye, J.
    Vranceanu, F.
    Camidge, D. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 4 - 5
  • [43] Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Bazhenova, L.
    Gettinger, S.
    Langer, C.
    Salgia, R.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G.
    Haney, J.
    Rivera, V.
    Haluska, F.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
    Camidge, R.
    Kim, H. R.
    Ahn, M.
    Yang, J. C.
    Han, J.
    Lee, J.
    Hochmair, M.
    Li, J. Y.
    Chang, G.
    Lee, K.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
  • [45] Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+Non-Small-Cell Lung Cancer (NSCLC)
    Felip, E.
    Bauer, T.
    Solomon, Benjamin
    Besse, B.
    James, L.
    Clancy, J.
    Klamerus, K.
    Martini, J. -F.
    Abbattista, A.
    Shaw, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S383 - S384
  • [46] Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
    Camidge, D. Ross
    Sugawara, Shunichi
    Kondo, Masashi
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James C. H.
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Kudou, Kentarou
    Asato, Takayuki
    Hupf, Bradley
    Vranceanu, Florin
    Fram, Robert J.
    Ohe, Yuichiro
    Popat, Sanjay
    LUNG CANCER, 2025, 201
  • [47] Brigatinib vs crizotinib in ALK TKI-naive ALK plus NSCLC: final results from ALTA-1L
    Popat, Sanjay
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James
    Han, Ji-Youn
    Hochmair, Maximilian
    Lee, Ki Hyeong
    Delmonte, Angelo
    Garcia Campelo, Maria
    Kim, Dong-Wan
    Griesinger, Frank
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander
    Gettinger, Scott
    Tiseo, Marcello
    Lin, Huamao
    Liu, Yuyin
    Vranceanu, Florin
    Camidge, D.
    LUNG CANCER, 2022, 165 : S27 - S28
  • [48] Brigatinib (BRG) in ALK plus crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
    Gettinger, Scott N.
    Huber, Rudolf M.
    Kim, Dong-Wan
    Bazhenova, Lyudmila
    Hansen, Karin Holmskov
    Tiseo, Marcello
    Langer, Corey J.
    Paz-Ares, Luis G.
    West, Howard
    Reckamp, Karen L.
    Weiss, Glen J.
    Smit, Egbert F.
    Hochmair, Maximilian
    Kim, Sang-We
    Ahn, Myung-Ju
    Kim, Edward S.
    Groen, Harry J. M.
    Pye, Joanna
    Vranceanu, Florin
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).
    Kim, Dong-Wan
    Tiseo, Marcello
    Ahn, Myung-Ju
    Reckam, Karen L.
    Hansen, Karin Holmskov
    Kim, Sang-We
    Huber, Rudolf M.
    West, Howard Jack
    Groen, Harry J. M.
    Hochmair, Maximilian J.
    Leighl, Natasha B.
    Gettinger, Scott N.
    Lange, Corey J.
    Paz-Ares, Luis G.
    Smit, Egbert F.
    Kim, Edward S.
    Reichmann, William G.
    Kerstein, David
    Haluska, Frank G.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] A PHASE I/II STUDY OF ALK INHIBITOR CH5424802 IN PATIENTS WITH ALK-POSITIVE NSCLC; SAFETY AND EFFICACY INTERIM RESULTS OF THE PHASE II PORTION
    Nishio, M.
    Kiura, K.
    Nakagawa, K.
    Seto, T.
    Inoue, A.
    Maemondo, M.
    Hida, T.
    Harada, M.
    Yoshioka, H.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 153 - 153
12345